Media Kit

Who are we?

We are the first human cryopreservation company safely made in Europe, and now covering also in the US. Founded in 2020 by Dr. Emil Kendziorra and Fernando Azevedo Pinheiro, our Berlin-based team of medical professionals and engineers is dedicated to providing high-quality cryopreservation services.

‍

What is human cryopreservation and why it’s not “freezing” people.

Human cryopreservation (also known as biostasis or cryonics) is an advanced medical procedure that puts a human into complete biological pause after their legal death. The purpose is to keep people preserved until medical technology has advanced enough to treat their cause of death and revive them. Cryonics provides the chance for patients to benefit from future technology and to potentially live a longer life than what is currently possible.

Extreme cold can preserve organic matter for long periods, but normal freezing causes ice crystals to form inside cells, damaging their structure and potentially destroying the organism. We don’t freeze people, even though we keep them at incredibly low temperatures. Instead, we keep them preserved using a procedure called vitrification. Vitrification is the transformation of a substance into a glass-like state. In cryonics, this is achieved by first replacing blood in the body with a type of medical grade antifreeze called a cryoprotectant solution.

‍

How does cryopreservation work?

1. Sign-up: Patients wishing to be cryopreserved sign up for a membership with Tomorrow.bio. We help them get the necessary paperwork in order, ensure there’s insurance or funds in place to pay for the cryopreservation procedure and stay ready to cryopreserve them whenever death occurs.
2. Dispatch: Most deaths can be predicted by medical conditions and circumstances. When there are signs that a patient might be dying, we dispatch one of our ambulances with a biostasis response team. They usually arrive before death occurs, allowing us to start the stabilization process as soon as the patient is legally pronounced dead.
3. Stabilisation: We cool the patient down as quickly as possible using ice and water. Then we initiate cardiopulmonary support (CPS) and infuse them with neuroprotective and anti-clotting medication. This stabilizes the patient, slows down the degradation process, and prepares the patient for cryoprotection.
4. Cryoprotection: Our ambulances are fully equipped to perform field cryopreservation, allowing us to get right to work: During our cryoprotection procedure, we will slowly replace the patient’s blood with cryoprotectant and cool them down further. The cryoprotectant protects the body during the cooldown.
5. Transport: We transport the patient to our storage facility in Switzerland. Transport can take place by ambulance or plane depending on the distance of the patient to the facility.
6. Cooldown: At the facility, the cryoprotected patients are placed in a cooldown chamber. As quickly as possible, we cool them to −120 °C, where they will undergo a process called vitrification, which is a glass-like transition of the body. Following this process, we slow the cooldown to about 1 °C per hour to avoid thermal stress. Cooldown finishes when the patient has reached −196 °C.
7. Storage: Patients are placed in a pod, which is then placed in a cryogenic dewar filled with liquid nitrogen. Here they are stored indefinitely, with no electricity required. The liquid nitrogen is regularly refilled by the on-site team or an automated system.

‍

European Biostasis Foundation

Tomorrow.bio stores its patients at the European Biostasis Foundation's underground facility in Switzerland. This facility was specially designed for long-term stability and security. Switzerland was chosen due to its security, socio-economic stability, strict oversight of non-profits, and low risk of natural disasters.

EBF is a non-profit organization that works together with Tomorrow.bio to provide a high quality and secure cryopreservation service.